{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:33Z","timestamp":1761895293781,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.03.032","type":"journal-article","created":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T16:49:47Z","timestamp":1306601387000},"page":"S111-S113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S1","title":["Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation"],"prefix":"10.1016","volume":"11","author":[{"given":"A. Megan","family":"Cornelison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Alma","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.032_bib1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.032_bib2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.03.032_bib3","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.clml.2011.03.032_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.03.032_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.032_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1999.17.1.284","article-title":"Treatment of Philadelphia chromosome\u2013positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine","volume":"17","author":"Kantarjian","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.032_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha\u2013based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.032_bib9","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1200\/jco.2008.26.15_suppl.7021","article-title":"Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) in patients (Pts) with the T315I mutation [abstract]","volume":"26","author":"Cortes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.032_bib10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.11620","article-title":"Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in early chronic phase","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.032_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V110.11.909.909","article-title":"A phase I dose escalation study of KW-2449, an oral multikinase inhibitor against FLT3, Abl,FGFR1, and Aurora in patients with relapsed\/refractory AML, treatment resistant\/intolerant CML, ALL, and MDS [abstract]","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib12","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739538, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations [abstract]","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood.V112.11.576.576","article-title":"Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]","volume":"112","author":"Van Etten","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V114.22.340.340","volume":"114;","author":"Guilhot","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood.V114.22.647.647","volume":"114","author":"Burchert","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.032_bib18","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Peudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.032_bib19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V114.22.1120.1120","article-title":"Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]","volume":"114","author":"Al-Ameri","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:14Z","timestamp":1761870134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":19,"alternative-id":["S2152265011000474"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.032","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}